Each week brings new discoveries that change what's possible in medicine. This week, we're covering a landmark study that reversed cartilage loss in aging joints and could one day eliminate the need for knee replacements, a major finding from the ASCO annual meeting linking GLP-1 medications to a 30% lower risk of breast cancer, an important warning about a popular joint supplement and Alzheimer's progression, and the news that the first human trials are now underway for a drug that could regrow missing teeth. A lot happened this week. Here's what researchers found.
Osteoarthritis affects one in five adults in the United States and costs roughly $65 billion in direct healthcare expenses each year. The disease happens when cartilage, the shock-absorbing cushion between bones in joints like the knee and hip, gradually wears away. Once it's gone, it doesn't grow back. The only treatments we've had are pain management and, eventually, surgical joint replacement.
That may be about to change.
A landmark study published June 12 in the journal Science by researchers at Stanford Medicine found that a single injection blocking an aging-related protein called 15-PGDH can reverse naturally occurring cartilage loss in the knee joints of older mice. The treatment didn't just slow the damage down. It fully restored the cartilage that had already worn away and dramatically improved the mice's movement and joint function.
The researchers also tested the approach after knee injuries resembling ACL tears, the kind common in athletes and active adults. The treatment stopped arthritis from developing in those joints entirely. And when the team exposed human cartilage samples collected from knee replacement surgeries to the same treatment, the tissue began producing new, functional cartilage.
Here is why this matters so much. 15-PGDH is what the research team calls a gerozyme, a protein whose levels rise with age and drive the gradual breakdown of tissues throughout the body. By blocking it, the treatment appears to unlock the cartilage's ability to repair itself, something scientists previously believed articular cartilage simply could not do.
An oral version of the drug is already being tested in clinical trials for age-related muscle weakness, meaning the path to human trials for cartilage regeneration is closer than it might seem. The researchers say that if successful in people, the approach could offer an alternative to knee and hip replacement surgery for millions of patients.
Read more: ScienceDaily / Stanford Medicine, Science, June 2026
The list of conditions that GLP-1 medications appear to protect against keeps growing. Originally developed for type 2 diabetes and later approved for obesity, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have already been shown to reduce the risk of heart attacks, strokes, kidney disease progression, and sleep apnea. Now, new research presented at the 2026 American Society of Clinical Oncology annual meeting adds breast cancer to that list.
Researchers at the University of Pennsylvania analyzed electronic health records from more than 110,000 women between the ages of 45 and 80. All had a BMI of 25 or higher and had undergone breast imaging within the Penn Medicine health system between 2022 and 2025. About 13.7% had been prescribed a GLP-1 medication.
Women taking GLP-1 drugs were roughly 30% less likely to develop breast cancer than women who were not. In the full study population the reduction in odds was 35%, and in a carefully matched analysis it was 30.5%. The results held up after accounting for age, race, ethnicity, BMI, breast density, and diabetes status, which means the finding is not simply explained by differences in who was taking the drugs.
Researchers are careful to note that because the study is observational, it cannot confirm that GLP-1 drugs directly prevent breast cancer. Some of the benefit may come from the weight loss these drugs produce, since excess body weight is a known risk factor for breast cancer after menopause. But the lead researcher, Dr. Elizabeth McDonald from Penn's Perelman School of Medicine, also noted that GLP-1 medications affect multiple biological pathways associated with cancer development, including inflammation and metabolic signaling, and that the weight loss explanation alone may not account for the full effect.
A clinical trial is now being designed to test whether the association reflects a true protective effect. In the meantime, researchers say the findings add compelling evidence to a growing conversation about GLP-1 drugs as potential cancer prevention tools.
Read more: SciTechDaily / JCO Oncology Practice / ASCO 2026, June 2026
More than 40 million Americans take glucosamine, an over-the-counter supplement widely marketed for joint pain and cartilage support. It is most commonly used by older adults, the same population most at risk for Alzheimer's disease. A new study from the University of Florida, published June 9 in the journal Nature Metabolism, raises important questions about that overlap.
Researchers used AI to analyze 12 years of anonymized health records from more than 65,000 patients diagnosed with either dementia or mild cognitive impairment. They found that people with mild cognitive impairment who were taking glucosamine were 25% more likely to progress to full Alzheimer's disease than those who were not taking the supplement. Among patients already diagnosed with Alzheimer's, glucosamine use was also linked to a 25% higher risk of dying within five years.
The research team didn't stop at the association. They went further to investigate a possible biological mechanism. Glucosamine crosses the blood-brain barrier and appears to fuel a process called hyperglycosylation, in which sugar molecules get attached to proteins and lipids in the brain. In Alzheimer's disease, this sugar-tagging pathway is already overactive. Glucosamine may be adding fuel to a fire that is already burning. When researchers blocked the enzyme responsible for this process in mice with Alzheimer's-like impairment, their memory improved.
There are important caveats here. Because this was a study of health records rather than a controlled clinical trial, the findings show an association and cannot prove that glucosamine causes faster cognitive decline. The researchers themselves are planning further studies, including following patients who discontinued the supplement to see whether stopping it slows decline.
For people with no cognitive concerns, this study does not provide grounds for alarm. But for anyone with mild cognitive impairment, a family history of Alzheimer's, or existing memory difficulties, it is worth discussing current supplement use with a healthcare provider. The researchers' message to that group is clear: millions of people at risk may be taking a supplement that could be affecting their disease course.
Read more: ScienceDaily / Nature Metabolism, June 2026
For decades, the dream of regrowing missing teeth has remained just that, a dream. Dentistry has offered solutions like implants, bridges, and dentures, but none of them replicate what a biological tooth does. Now, for the first time, a drug designed to stimulate tooth regrowth is moving into Phase II human clinical trials.
The drug is called TRG035, developed by Toregem BioPharma, a spin-out from Kyoto University in Japan. The company recently raised $5.3 million to support the upcoming trials, bringing total funding (including grants and subsidies) to over $29 million.
Here's how it works. Humans develop two sets of teeth in their lifetime, but most people don't know we actually have the beginnings of a third set already embedded in our jaws. A protein called USAG-1 normally keeps those dormant tooth buds from developing. TRG035 is an antibody that blocks USAG-1, theoretically allowing those sleeping tooth buds to wake up and grow.
The approach has worked in animals. Mice and ferrets treated with the drug successfully regrew missing teeth. Phase I trials in healthy adults with at least one missing tooth concluded without serious adverse events, paving the way for Phase II.
The upcoming Phase II trial will test TRG035 in patients with severe congenital hypodontia, a genetic condition where people are born with six or more permanent teeth missing. If these trials succeed, the researchers plan to eventually expand to children aged 2 to 7 with the same condition. The ultimate goal is wider availability, though the researchers are being realistic about the timeline. They're aiming for general use around 2030, but that date depends on regulatory approval and successful trial data.
For now, this is early-stage research. But for millions of people who have lost teeth to decay, disease, or injury, the possibility of biological regrowth rather than artificial replacement represents a genuinely new frontier in dentistry.
Read more: Dentistry.co.uk, June 2026
This week’s breakthroughs challenge our limits, from regrowing cartilage and teeth to reevaluating common medications and supplements. Yet, these advancements rely entirely on the clinical research. Patients hold the true power to transform these lab discoveries into real-world treatments by participating in trials. Explore our patient stories, communities and researcher spotlights to learn how you can help move science forward. See you next week for another edition of The Weekly Wing. 💚
Cartilage has long been considered unable to repair itself. In a June 2026 Stanford Medicine study, a single injection blocking a protein called 15-PGDH reversed cartilage loss in older mice and prompted new cartilage growth in human tissue samples. It is early-stage research and not yet available to patients, but it suggests cartilage regeneration may be possible in the future.
A 2026 University of Pennsylvania study presented at ASCO found women taking GLP-1 medications were roughly 30% less likely to develop breast cancer than those who were not. The study is observational, so it shows a strong association rather than proof of cause. A clinical trial is being designed to test whether the effect is real.
A June 2026 University of Florida study linked glucosamine use to a 25% higher chance of progressing from mild cognitive impairment to Alzheimer's, and a higher five-year mortality risk in people already diagnosed. The study shows an association, not proof. Anyone with memory concerns or a family history of Alzheimer's should talk to a healthcare provider before continuing the supplement.
Yes, one is in human trials. TRG035, developed by Toregem BioPharma, blocks a protein called USAG-1 to activate dormant tooth buds already in the jaw. It regrew teeth in animals and has entered Phase II human trials in 2026.
Researchers are aiming for general availability around 2030, but that depends on regulatory approval and successful trial results. As of June 2026, the drug is still in Phase II testing.
No. All four are still in research or clinical-trial stages. They point to where medicine is heading, but none is currently available as a standard treatment.
Clinical trials need volunteers to move new treatments forward. A good first step is learning how studies work and what participation involves through resources like PatientWing's clinical research education hub, then talking with your doctor about options that fit your condition and goals.
